Using Semaglutide to reduce damage from acute ischemic stroke
Official title: The Safety and Efficacy of Acute Subcutaneous Administration of Semaglutide in Non-diabetic Patients With Acute Ischemic Stroke: A Multicentre, Phase 2, Prospective, Randomized, Open-label, Blinded Endpoint Trial
Run by University of Aarhus · NCT05630586 · Data updated 2026-11-12
This study is testing if Semaglutide can help reduce brain damage in people who have had an acute ischemic stroke and had no to moderate disability before the stroke.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 380 (estimated) |
| Sponsor | University of Aarhus Academic / other |
| Locations | 1 site (Aarhus) |
| Status | Recruiting |
| Started | April 12, 2023 |
| Main results expected | September 2025 |
| Study ends | December 2027 |
| Registry record updated | April 25, 2023 |
| Trial ID | NCT05630586 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older who have experienced an acute ischemic stroke with disabling neurological deficits and no prior diabetes.
✕Probably not a fit
Patients with known diabetes, severe neurodegenerative diseases, or significant renal impairment are unlikely to benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial investigates the safety and efficacy of Semaglutide in non-diabetic patients who have experienced an acute ischemic stroke. The ASSET trial is a national, multicenter effort aimed at determining whether Semaglutide can help minimize brain damage caused by the stroke. Participants will receive Semaglutide alongside standard care within 4.5 hours of stroke onset. The study focuses on patients with disabling neurological deficits but who had no to moderate disability prior to the stroke.
Why it matters
Potential benefit: If successful, this treatment could significantly reduce long-term disability in stroke patients.
How similar studies have gone: While the use of Semaglutide in this context is novel, other studies have explored similar neuroprotective strategies in stroke management.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male and female patients (≥ 18 years) at the time of signed informed consent/proxy consent * Acute ischemic stroke with disabling neurological deficits (defined as an impairment of one or more of the following: language, motor function, cognition, gaze, vision, neglect, or ataxia) * Onset/last seen well to randomization \< 4.5 hours * None to moderate disability in daily living before symptom onset (pre-stroke modified Rankin Scale 0-3) Exclusion Criteria: * Diabetes (known) or plasma/point of care test-glucose \>11.1 mmol/L at admission * BMI\< 22 * History of pancreatitis, medullary thyroid carcinoma * Predisposition or known Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) * Short remaining life expectancy (\< 12months) and/or severe neurodegenerative disease * Pregnancy or planned pregnancy within 12 months or breastfeeding * Renal impairment measured as estimated glomerular filtration rate (eGFR) value of \<30 mL/min/1.73 m2
Where it's running
-
Aarhus University Hospital
Aarhus, Denmark Recruiting
Study contacts
- Principal investigator: Claus Z Simonsen, Professor — Aarhus University Hospital
- Study coordinator: Thomas Mellemkjaer, MD
- Email: thomas.mellemkjaer@rm.dk
- Phone: 004551430175
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Short-Term outside-in nerve stimulation for acute ischemic stroke
This trial tests whether a 5-day external trigeminal nerve stimulation given after stroke can help more patients recover better than a sham treatment.
-
Sevoflurane vs. Propofol for anesthesia in stroke patients undergoing clot-removal
This study tests whether sevoflurane or propofol used for anesthesia during endovascular treatment of an acute ischemic stroke affects the final brain damage and recovery.
-
Safety of adding NRICM301 to standard care for adults with acute ischemic stroke
This study tests whether adding NRICM301, a traditional Chinese medicine formula, to usual care is safe for adults with acute ischemic stroke.
-
Intracranial Recanalization with LT3001 in Acute Ischemic Stroke
This phase II study tests whether LT3001 given to adults with acute ischemic stroke can help reopen blocked brain arteries.
-
Mobilisation After Endovascular Stroke Treatment
This study checks whether moving around 12 hours after endovascular stroke treatment is as safe as moving around 24 hours for people with an acute ischemic stroke.
-
Endovascular therapy plus standard care vs standard care alone for distal and medium vessel strokes
In people with acute ischemic stroke due to distal or medium vessel blockages, this study tests whether adding endovascular treatment to the usual medical care helps improve outcomes compared with medical care alone.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.